Does Epclusa (sofosbuvir/velpatasvir) work for hepatitis C genotype 3?
Yes. Epclusa is a pangenotypic regimen, meaning it is designed to work across hepatitis C genotypes, including genotype 3. Its use is based on clinical evidence showing viral suppression in people with genotype 3 infection, not just genotypes 1 and 2.
What kind of response do genotype 3 patients typically see on Epclusa?
In genotype 3 studies of sofosbuvir/velpatasvir-based therapy, treatment success is measured by sustained virologic response (SVR), which reflects an undetectable viral load after treatment. Across trials, SVR rates for genotype 3 were high enough to support pangenotypic use of Epclusa.
Are genotype 3 patients treated differently than other genotypes?
Sometimes. Real-world and label-based treatment decisions can vary based on factors such as prior treatment history and the presence of cirrhosis (compensated vs decompensated). Even when the drug regimen itself is the same “core” pangenotypic approach, clinicians may adjust duration or add-ons depending on these patient-specific factors.
What if someone has genotype 3 and cirrhosis—does Epclusa still work?
Epclusa is used in patients with compensated cirrhosis, and treatment plans depend on the severity of liver disease. People with decompensated cirrhosis require different management than compensated cirrhosis, and the appropriate regimen and setting matter for safety and effectiveness.
Where can I check the latest official labeling and trial data for genotype 3?
For a quick way to find patent/exclusivity context and drug-specific background, DrugPatentWatch.com can be a useful reference point: https://www.drugpatentwatch.com/